Clinical Advances and State-of-Art Management in Genitourinary Cancers
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".
Deadline for manuscript submissions: 25 August 2025 | Viewed by 1527
Special Issue Editors
Interests: genitourinary cancers; tumor immune microenvironment; cancer immunology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Genitourinary (GU) malignancies represent a variety of tumors within the urinary and male reproductive systems, requiring individualized treatment plans to meet the distinct needs of each patient. Although most GU malignancies are well managed in the early stages, the advanced stages of many such cancers have a poor prognosis. Limited treatment options and poor prognosis represent an unmet need in advanced GU malignancies.
The development of novel therapies for advanced GU cancers relies on comprehension of underlying biological mechanisms, and several research efforts have focused on genomic profiling, diagnostic biomarkers, tumor immune microenvironment (TIME), and molecular pathways of oncogenesis.
The focus of this Special Issue is to consider research efforts pertaining to: (a) tumor biology, genomic characterization, and microenvironment; and (b) exploration of novel therapies in genitourinary malignancies.
Dr. Jad Chahoud
Guest Editor
Dr. Adnan Fazili
Guest Editor Assistant
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- genitourinary malignancies
- tumor–immune microenvironment (TIME)
- tumor biology
- genomic characterization
- targeted drug therapy
- immunotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
